Advertisement

European Radiology

, Volume 28, Issue 2, pp 861–868 | Cite as

Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection

  • Hyungjin Kim
  • Kum Ju Chae
  • Soon Ho Yoon
  • Miso Kim
  • Bhumsuk Keam
  • Tae Min Kim
  • Dong-Wan Kim
  • Jin Mo Goo
  • Chang Min ParkEmail author
Oncology

Abstract

Objectives

To find predictors of non-diagnostic repeat biopsy specimen acquisition for mutational analysis and detection of epidermal growth factor receptor (EGFR) T790M mutation.

Methods

We retrospectively reviewed 90 non-small cell lung cancer patients harbouring EGFR mutations who underwent repeat cone-beam CT-guided transthoracic needle biopsy. Clinical characteristics as well as biopsy-related factors were compared between patients with and without diagnostic specimen acquisition and between patients with and without T790M mutation. After univariate analysis, multivariate logistic regression analysis was performed to reveal independent predictors.

Results

Diagnostic biopsy specimens for mutational test were obtained in 90% (81/90) of patients, of which 62% (50/81) possessed T790M mutation. None of the analysed variables were significantly associated with non-diagnostic specimen acquisition. For T790M detection, duration of EGFR tyrosine kinase inhibitor treatment (p = 0.066), duration of total chemotherapy (p = 0.026), tumour size (p = 0.066), and metastatic lung lesion as a biopsy target (p = 0.029) showed p values less than 0.10. Multivariate analysis revealed that target tumour size (odds ratio, 0.765; p = 0.031) was an independent predictor of T790M mutation. Metastatic lesions as biopsy targets (odds ratio, 4.194; p = 0.050) showed marginal statistical significance.

Conclusions

Non-diagnostic repeat biopsy specimen acquisition was not related to the clinical or technical factors. However, detection of T790M at repeat biopsy might be associated with smaller target tumour size and selection of metastatic lesions as biopsy targets.

Key Points

Cone-beam CT-guided repeat biopsy yielded high diagnostic specimen acquisition rate.

Biopsy-related features were associated with the detection of T790M mutation.

Target tumour size was an independent predictor of the T790M detection.

Biopsy targeting metastatic lung nodules might help detect the T790M mutation.

Keywords

Non-small-cell lung carcinoma Epidermal growth factor receptor Protein kinase inhibitor Drug resistance Image-guided biopsy 

Abbreviations

OS

Overall survival

NSCLC

Non-small cell lung cancer

EGFR

Epidermal growth factor receptor

TKI

Tyrosine kinase inhibitor

PFS

Progression-free survival

ATP

Adenosine triphosphate

CBCT

Cone-beam computed tomography

PTNB

Percutaneous transthoracic needle biopsy

PNA

Peptide nucleic acid

PCR

Polymerase chain reaction

SUV

Standardised uptake value

Notes

Acknowledgements

We would like to thank Chris Woo, B.A., for editorial assistance.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is Chang Min Park.

Conflict of interest

The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

Funding

This study has received funding by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HC15C3390) and a grant of the Industrial Strategic technology development program, funded by the Ministry of Trade Industry and Energy (MI), Republic of Korea (grant number: 10041618).

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained

Study subjects or cohorts overlap

Some study subjects or cohorts have been previously reported in a journal article (N Engl J Med 372:1689-1699).

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29CrossRefPubMedGoogle Scholar
  2. 2.
    Lin Y, Wang X, Jin H (2014) EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 4:411–435PubMedPubMedCentralGoogle Scholar
  3. 3.
    Zheng D, Ye X, Zhang MZ et al (2016) Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep 6:20913CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Stewart EL, Tan SZ, Liu G, Tsao MS (2015) Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res 4:67–81PubMedPubMedCentralGoogle Scholar
  5. 5.
    Arcila ME, Oxnard GR, Nafa K et al (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17:1169–1180CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Sequist LV, Waltman BA, Dias-Santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Yu HA, Arcila ME, Rekhtman N et al (2013) Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 19:2240–2247CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Yun CH, Mengwasser KE, Toms AV et al (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 105:2070–2075CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792CrossRefPubMedGoogle Scholar
  10. 10.
    Wang S, Cang S, Liu D (2016) Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. J Hematol Oncol 9:34CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Janne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699CrossRefPubMedGoogle Scholar
  12. 12.
    Sequist LV, Soria JC, Goldman JW et al (2015) Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 372:1700–1709CrossRefPubMedGoogle Scholar
  13. 13.
    Chouaid C, Dujon C, Do P et al (2014) Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer 86:170–173CrossRefPubMedGoogle Scholar
  14. 14.
    Hasegawa T, Sawa T, Futamura Y et al (2015) Feasibility of rebiopsy in non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors. Intern Med 54:1977–1980CrossRefPubMedGoogle Scholar
  15. 15.
    Hata A, Katakami N, Yoshioka H et al (2013) Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 119:4325–4332CrossRefPubMedGoogle Scholar
  16. 16.
    Kawamura T, Kenmotsu H, Taira T et al (2016) Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. Cancer Sci 107:1001–1005CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kuiper JL, Heideman DA, Thunnissen E et al (2014) Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 85:19–24CrossRefPubMedGoogle Scholar
  18. 18.
    Redig AJ, Costa DB, Taibi M et al (2016) Prospective study of repeated biopsy feasibility and acquired resistance at disease progression in patients with advanced EGFR mutant lung cancer treated with erlotinib in a phase 2 trial. JAMA Oncol 2:1240–1242CrossRefPubMedGoogle Scholar
  19. 19.
    Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K (2013) Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 82:294–298CrossRefPubMedGoogle Scholar
  20. 20.
    Yoon HJ, Lee HY, Lee KS et al (2012) Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology 265:939–948CrossRefPubMedGoogle Scholar
  21. 21.
    Choo JY, Park CM, Lee NK, Lee SM, Lee HJ, Goo JM (2013) Percutaneous transthoracic needle biopsy of small (≤1 cm) lung nodules under C-arm cone-beam CT virtual navigation guidance. Eur Radiol 23:712–719CrossRefPubMedGoogle Scholar
  22. 22.
    Kim H, Park CM, Lee SM, Goo JM (2015) C-arm cone-beam CT virtual navigation-guided percutaneous mediastinal mass biopsy: diagnostic accuracy and complications. Eur Radiol 25:3508–3517CrossRefPubMedGoogle Scholar
  23. 23.
    Kim JI, Park CM, Kim H, Lee JH, Goo JM (2017) Non-specific benign pathological results on transthoracic core-needle biopsy: how to differentiate false-negatives? Eur Radiol. doi: 10.1007/s00330-017-4766-3 PubMedCentralGoogle Scholar
  24. 24.
    Han HS, Lim SN, An JY et al (2012) Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 7:355–364CrossRefPubMedGoogle Scholar
  25. 25.
    Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ (2011) Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 17:6298–6303CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Oxnard GR, Arcila ME, Sima CS et al (2011) Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17:1616–1622CrossRefPubMedGoogle Scholar
  27. 27.
    Li W, Ren S, Li J et al (2014) T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 84:295–300CrossRefPubMedGoogle Scholar
  28. 28.
    Chmielecki J, Foo J, Oxnard GR et al (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Yoshida T, Tanaka H, Kuroda H et al (2016) Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs. Lung Cancer 100:14–19CrossRefPubMedGoogle Scholar
  30. 30.
    Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17:5530–5537CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14:2895–2899CrossRefPubMedGoogle Scholar
  32. 32.
    Ma C, Wei S, Song Y (2011) T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis 3:10–18PubMedPubMedCentralGoogle Scholar
  33. 33.
    Kim EY, Cho EN, Park HS et al (2016) Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. BMC Cancer 16:27CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Nosaki K, Satouchi M, Kurata T et al (2016) Re-biopsy status among non-small cell lung cancer patients in Japan: a retrospective study. Lung Cancer 101:1–8CrossRefPubMedGoogle Scholar
  35. 35.
    Sundaresan TK, Sequist LV, Heymach JV et al (2016) Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res 22:1103–1110CrossRefPubMedGoogle Scholar

Copyright information

© European Society of Radiology 2017

Authors and Affiliations

  1. 1.Department of Radiology, Seoul National University College of Medicine, and Institute of Radiation MedicineSeoul National University Medical Research CentreSeoulKorea
  2. 2.Department of Radiology, Institute of Medical Science, and Research Institute of Clinical MedicineChonbuk National University Medical School and HospitalJeonjuKorea
  3. 3.Seoul National University Cancer Research InstituteSeoulKorea
  4. 4.Department of Internal MedicineSeoul National University HospitalSeoulKorea

Personalised recommendations